Thomas Nissley is a retired pastor, educator, and clinical psychotherapist who currently works as a preservationist of antique and classic homes and as a realtor. Tom is a graduate of Franklin and Marshall College, Princeton Theological Seminary, and the University of Neuchatel in Switzerland. Tom also studied at the Western Institute for Gestalt and Family Therapy and is clinically certified in Transactional Analysis. Currently a director of the USA Transactional Analysis Association, a trustee of the CT Association for Historic Preservation, co-curator for the Gores Pavilion, and a member of the New Canaan Historical Society, Tom has a deep passion for community service and involvement.
Margaret Osius
Founder and Principal of Osius & Associates, Meg advises corporate and banking clients, structuring international green-field infrastructure, and PPP projects, as well as facility upgrades in the oil and gas, power, telecommunications and other sectors. Prior to establishing her own firm, Meg was with the Global Banking Division of J.P. Morgan Chase Manhattan Bank where she originated export and project finance transactions and assisted clients with risk management. She has extensive experience with workout and distressed companies. Meg is presently a Director of Waterloo Holdings Ltd., Bermuda, and British Caribbean Bank (BCB). Previously she was Chair of the Technical Advisory Panel (TAP) of the World Bank managed Public Private Infrastructure Advancement Fund (PPIAF). Meg received an M.B.A. from INSEAD, the European Institute of Business Administration, in Fontainebleau, France. Her B.A. degree is from Princeton University. She is a member of the Council on Foreign Relations.
Brian Silver
Brian Silver is the CFO of Freeline Therapeutics, a gene therapy company focused on curing rare diseases, including hemophilia and inborn errors of metabolism. Prior to Freeline Therapeutics, Brian was partner at Perella Weinberg Partners, New York Office responsible for equity and debt capital markets. He also served as a Managing Director in Morgan Stanley’s Healthcare Investment Banking Group where he advised a broad range of biopharmaceutical and pharmaceutical services clients on mergers and acquisitions, initial public offerings, the equity and capital markets, and royalty financing. Brian graduated from Harvard and the University of Chicago Law School.